The Pharma Innovation
نویسنده
چکیده
The aim of our study was to improve the treatment of patients with stable Angina Pectoris functional class III with Hypertension and prevention of nitratoresistance development with usage of antioxidant (Mexicor) and NO-donor (L-arginine). The study involved 63 patients with stable angina pectoris FC III with concomitant Hypertension. All patients were divided into two groups. Patients of I group received basic therapy, patients of group II except basic therapy received Mexicor and L-arginin. The effectiveness of antianginal therapy was assessed by dynamic of clinical indicators, tolerance to physical activity, endothelial function and the level of oxidative stress. Influenced by Mexicor and L-arginine patients better upgraded clinical, hemodynamic and biochemical predictors of nitratoresistance compare with the influence of only basic therapy. Keyword: Stable Angina, Hypertension, Nitratoresistance.
منابع مشابه
The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance
In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters' patent expirations, this paper examines the moderating role of firms' absorptive capacity in external innovation activities of Big Pharma firms. The study indicates a rising interest of Big Pharma in acquisitions of and alliances with biotechnology companies. Unfortunately, this increased interest is not...
متن کاملChanging the Model in Pharma and Healthcare - Can We Afford to Wait Any Longer?
Innovation in healthcare delivery and Pharma requires rethinking old problems, retooling with new methodologies and revisiting the process models that are foundations of our existing knowledge discovery and clinical practice. The continuing proliferation of ubiquitous sensor data, mobile devices and the advent of 3D printing of drugs, together with a social mind shift in data ownership are clea...
متن کاملRecent Trends in Collaborative, Open Source Drug Discovery
The pharmaceutical sector has traditionally played a predominant role in screening compounds against a molecular target and optimizing chemistry to develop drugs. The basic research studies in the academic sector have provided the pharmaceutical companies with many biological targets with potential impact on therapeutics. These welldefined contributions of the pharmaceutical and academic sector...
متن کاملAn Idealized Design For A Networked Change Approach In A Pharmaceutical R&D Organization
Big Pharma is confronted with an unsustainable business model. This is characterized by high attrition rates for medicines under development, increasing regulatory thresholds, and technical complexity of treating diseases of unmet medical need (e.g. Alzheimer’s ). This has driven up the cost of drug development. Pharma companies are using various approaches to stimulate innovation while also ac...
متن کاملRestructuring and innovation in pharmaceuticals and biotechs: The impact of financialisation
In this paper we explore whether a financialisation perspective can provide a more empirically satisfying account of recent developments in the pharmaceutical industry than the more commonly used resource-based or transaction cost approaches. Specifically, we note the evolution of the pharmaceutical industry structure from giant vertically integrated firms, selling patent protected blockbuster ...
متن کاملChanging Strategies of Big Pharma
The life sciences are transforming pharmaceutical companies in terms of both internal R&D processes and strategies for external knowledge capture mergers, acquisitions, strategic alliances and licensing. Dr. Mittra’s research on life science innovation and the pharmaceutical industry reveals that these are a cluster of related activities that provide various strategic options for managing innov...
متن کامل